Exploring Shorter Product Development Cycles and an In-House Production System
First written in FY2021. 2 of 5 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2023-Q3.
0 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「In addition to effectively using this manufacturing facility, the company plans to establish an R&D facility headed by a person with extensive R&D experience who has served as an adviser, among other roles, in the cosmetics and quasi-drugs fields at several major cosmetics manufacturers. The facility will conduct advanced ingredient research and develop proprietary formulations, enabling the company to bring products with high customer satisfaction to market more quickly.」
Continues the policy of conducting ingredient research and proprietary formulation development using the acquired manufacturing site and R&D center. - FY2023-Q2AdvancedAnnual report
「Through the acquisition of all shares of 株式会社ユイット・ラボラトリーズ in April 2022 and its conversion into a consolidated subsidiary, the group acquired a manufacturing site along with manufacturing expertise. In addition to effectively using this manufacturing facility, the group plans to establish an R&D facility headed by a person with extensive R&D experience who has served as an adviser, among other roles, in the cosmetics and quasi-drugs fields at several major cosmetics manufacturers. The facility will conduct advanced ingredient research and develop proprietary formulations, enabling the group to bring products with high customer satisfaction to market more quickly.」
The company has progressed to establishing and operating an R&D facility using the acquired manufacturing site. It is putting in place a concrete system to accelerate product development by combining manufacturing facilities with ingredient research and proprietary formulation development. - FY2022-Q3AchievedAnnual report
「The acquisition of all shares of 株式会社ユイット・ラボラトリーズ will enable the company to assemble skincare brands at different price points that can be differentiated within the group according to sales channels and customer segments. It will also enable faster development of cosmetics and quasi-drugs with new core themes by using the company’s manufacturing facilities to accelerate product development and applying its OEM expertise to new product development.」
On 1 April 2022, the company acquired all shares of 株式会社ユイット・ラボラトリーズ for ¥860 million and included it in the scope of consolidation. The company has progressed from considering and resolving on the acquisition to completing it as a specific milestone. - FY2022-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 4 March 2022, the company resolved to acquire all shares of 株式会社ユイット・ラボラトリーズ and entered into a share transfer agreement on the same date. In addition to assembling skincare brands at different price points that can be differentiated within the group according to sales channels and customer segments, the acquisition will enable the company to accelerate product development using the company’s manufacturing facilities and to develop cosmetics and quasi-drugs with new core themes more quickly by applying its OEM expertise to new product development.」
Regarding the previous policy of considering M&A and an in-house production system, the company reports concrete progress through the resolution to acquire all shares of 株式会社ユイット・ラボラトリーズ and the execution of the agreement. The acquisition was scheduled for 1 April 2022, with consideration of ¥860 million. - FY2021First statedAnnual report
「We will consider the optimal approach, including M&A involving a company with cosmetics manufacturing facilities and the establishment of our own factory. We intend to shorten the product development cycle by manufacturing small-volume, diverse products in-house and mass-produced products through contract manufacturers.」
In response to the current bottleneck of relying primarily on contract manufacturing, the company presents a policy combining M&A, its own factory, in-house production of small-volume, diverse products and contract manufacturing of mass-produced products.